



## reMYND

### ACTIVITY:

Developing disease modifying therapeutics for Alzheimer's and Parkinson's disease

### MANAGEMENT:

- Koen De Witte, M.Sc., MBA, Managing Director
- Gerard Griffioen, Ph.D., CSO DD
- An Tanghe, Ph.D., Manager CRO
- Hans van der Saag, CFO and Legal Counsel
- Hein Duhamel, Ing., Head of QA and ICT

### EMPLOYEES:

24 in Leuven, 4 in Poland

### SHAREHOLDERS:

- Founders, Friends and Family
- K.U.Leuven
- Gemma Frisius Fund

### FOUNDERS:

- Prof. Fred Van Leuven, Ph.D.,
- Prof. Joris Winderinckx, Ph.D.,
- Stefaan Wera, Ph.D.

### CONTACT DETAILS:

reMYND NV  
Gaston Geenslaan 1  
B-3001 Leuven (Heverlee)  
Belgium  
T: (+32) 16 75 14 20  
F: (+32) 16 75 14 21  
www.remynd.com

## About reMYND

reMYND, founded in 2002 as a spin-off from the K.U.Leuven, actively drives the development of disease modifying treatments against Alzheimer's (AD) and Parkinson's Disease (PD), either through its own Drug Discovery&Development or as a Contract Research Organisation (CRO):

- The in-house pipeline of the own Drug Discovery&Development consists of 4 disease modifying compounds against Alzheimer's Disease (counteracting Tau toxicity) and 2 against Parkinson's Disease (counteracting  $\alpha$ -synuclein toxicity). As such, reMYND develops AD treatments targeting the Tau-pathway, ensuring there is no conflict of interest with the  $\beta$ -amyloid treatments of the CRO clients. The lead PD compound is planned to enter Phase I in 2010/2011. The lead AD compound will follow one year later.
- As a CRO, reMYND offers in vivo efficacy, pharmacokinetic and toxicity testing on its proprietary mouse models for Alzheimer's Disease, targeting primarily the  $\beta$ -amyloid pathway for AD.

## Drug Discovery & Development


reMYND focuses entirely on disease-modifying treatments with the aim to decelerate – or stop when possible – neurodegeneration. As such, we respond to major unmet medical needs, as all marketed treatments and the majority of products under development are mainly symptomatic. Our current lead compound in PD even completely inhibits the progression in the relevant animal models.

In discovery, hits are identified in patent-protected, humanized yeast cell-lines, subsequently optimized in human neuronal cell-lines and finally validated in vivo in proprietary animal models. reMYND has focused since 2002 on PD (targeting  $\alpha$ -synuclein mediated cytotoxicity) and AD (targeting Tau mediated cytotoxicity). This visionary strategy has procured reMYND several years ahead of competition, as the scientific community starts only now to gradually move from  $\beta$ -amyloid towards Tau as the most promising target in AD. In addition, our platform can be adapted to target virtually any disease associated with protein-misfolding, such as Diabetes, Huntington's disease, and ALS. We are currently expanding our discovery activities outside CNS to further diversify our risk profile.

reMYND focuses pre-clinical development on 2 compounds active against  $\alpha$ -synuclein in PD and 4 compounds active against Tau in AD. We have demonstrated full disease-modifying proof-of-concept for our lead PD drug and for our lead AD drug with no apparent side effects, and early efficacy indications for another compound family in AD. All compounds represent small chemical entities with drug-able chemical structures obeying “Lipinski rule of 5”.

reMYND’s pipeline was and is fueled by revenues from contract research and by governmental grants.

### Product Pipeline




### Contract Research

reMYND offers in vivo drug testing in a variety of Alzheimer mouse models based on the clinical APP-London mutation, either as a single APP model or in combination with PS1 or TAU. Testing includes biochemical and immunohistochemical read-outs of brain pathology, as well as behavioral testing. reMYND has signed contracts with top pharma and biotech companies active in CNS worldwide.

In addition, reMYND has signed several licenses on Radarscreen, its proprietary genotoxicity screen, which was developed for its own discovery program, as a superior alternative to other commercially available solutions addressing genotoxicity liabilities of xenobiotics. Commercial kits are currently under development with Biopredic (France) as a partner.

### Collaborations

For housing, breeding and characterizing transgenic mice, reMYND collaborates with the Medical Research Institute, Warsaw, Poland and with the Katholieke University of Leuven, Belgium. The DDD works together with 10 scientific and clinical key opinion leaders, as well in Europe as in the US. Over the last 3 years, reMYND has signed research agreements with more than 20 biotech or pharma companies and 6 academic institutes located in the US, Europe or Japan.



### COMPANY HIGHLIGHTS:

- Leading, biology-driven discovery and development of disease modifying treatments
- Focus on Alzheimer’s and Parkinson’s disease with pipeline of 4 and 2 compound families respectively
- Lead PD compound ready to enter the clinic in 2010/2011
- Platform readily applicable to other protein misfolding diseases, such as Diabetes
- Contract Research for 3rd parties in proprietary, validated Alzheimer animal models
- Extensive network of academic, clinical and industrial collaborations

### MEDIA AND INVESTOR INQUIRIES:

Vera Gijsemans  
remynd@remynd.com

### CONTRACT RESEARCH INQUIRIES:

An Tanghe, CRO manager  
An.Tanghe@remynd.com